(Adds details, shares)
Aug 11 Biodel Inc said its experimental
insulin formulation was found more effective than current
therapies in controlling glucose after two meals, in a mid-stage
Shares of the specialty pharmaceutical company rose 10.5
percent before the bell.
The study was testing the drug, BIOD-531, against Eli Lilly
and Co's Humalog Mix 75/25 in type 2 diabetes patients
with moderate insulin resistance who use 50-200 units of insulin
In type 2 diabetes, the most common form of the disease, the
body does not use insulin properly, leading to high levels of
Basal insulin, or long-acting insulin therapies, are usually
prescribed to keep blood sugar levels in control between meals.
Prandial insulin, or short-acting insulin therapies, are
administered before meals to manage mealtime glucose.
Type 2 diabetes patients are usually given both basal and
prandial insulin in a single injection such as Humalog Mix
75/25, Biodel said.
Humulin R U-500 is the only concentrated insulin available
in the United States, the company said.
The therapy is used to treat type 2 diabetes patients with
severe insulin resistance, who need greater than 200 units of
Danbury, Connecticut-based Biodel's shares closed at $1.91
on the Nasdaq on Friday.
(Reporting by Natalie Grover in Bangalore; Editing by Kirti